Multiple Myeloma

Latest News

February 13th 2023

Non–BCMA-Targeting Bispecific Antibodies in R/R MM

By Sagar Lonial, MD, FACP, Sandy Wong, MD, Caitlin Costello, MD

A brief review of non–BCMA-targeted bispecific antibodies under investigation in patients with relapsed/refractory multiple myeloma.

Latest Videos

Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma

MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

Clinical Pearls for Community Physicians Treating Patients With RRMM With CAR T-Cell Therapy

Ciltacabtagene Autoleucel in Patients With MM: Efficacy and Safety Data From CARTITUDE-1

A panel of 4 experts on multiple myeloma seated at a long table

Multiple Myeloma: Treatment Considerations and Role of MRD

Consolidation and Maintenance Therapy Considerations in Multiple Myeloma

Saad Usmani, MD, MBA, FACP, an expert on multiple myeloma

Overview of Relapsed/Refractory Multiple Myeloma

How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

Navigating CAR-T Therapy in RRMM: Patient Counsel and Managing AEs

Available Options for CAR T-Cell Therapy in Patients With RRMM

Patient Case Presentation: A 62-Year-Old Woman With High-Risk Multiple Myeloma

CME Content

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Iowa

Sapna Patel, MD; Rakesh Bagai, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | New York

Yana G. Najjar, MD; Deepa Jagtap, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Minnesota

Yana G. Najjar, MD; Anand Patel, MD

In-Person Event

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Texas

Yana G. Najjar, MD; Kara Schenk, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Washington

Yana G. Najjar, MD; Albert Dekker, MD

Video

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Richard S. Finn, MD; Anthony B. El-Khoueiry, MD; Pierre Gholam, MD; Lipika Goyal, MD

Multimedia

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD

Multimedia

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Kathleen N. Moore, MD, MS, FASCO; Susana Banerjee, MBBS, MA, FRCP, PhD; David M. O’Malley, MD; Ritu Salani, MD, MBA

Multimedia

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS, FASCO; David M. O’Malley, MD

Multimedia

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD

Multimedia

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA

Video

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Mark G. Kris, MD; Justin Gainor, MD; Isabel Preeshagul, DO, MBS; Helena A. Yu, MD

Multimedia

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Kathleen N. Moore, MD, MS, FASCO; Prof Susana Banerjee, MBBS, MA, FRCP, PhD

Video

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Louisiana

Jacob Sands, MD; Uday Dandamudi, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Colorado

Sapna Patel, MD; Jyothi Dodlapati, MD

Video

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Montana and Wyoming

Jacob Sands, MD; Brian Vicuna, MD

In-Person + Virtual Event

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

December 5, 2025

In-Person + Virtual Event

Breast Cancer Symposia in San Antonio

December 8-11, 2025

Multimedia

Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?

Jae H. Park, MD

Virtual Event

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

December 19, 2025

Multimedia

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Tiffany A. Traina, MD, FASCO; Demetria Smith-Graziani, MD, MPH

Video

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Mark Agulnik, MD; Shaina A. Rozell, MD, MPH

Video

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Lee M. Zuckerman, MD

Multimedia

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Daniel Lefler, MD; Shaina A. Rozell, MD, MPH; Lee M. Zuckerman, MD

Case-based Simulation

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Mark Agulnik, MD; Daniel Lefler, MD

In-Person Event

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

January 22, 2026

In-Person Event

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Video

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Naval G. Daver, MD; Jessica Altman, MD; Amir T. Fathi, MD; Gail J. Roboz, MD; Joshua Zeidner, MD

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Video

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

In-Person Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

More News

Patient Profile 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma

ByMelissa Alsina, MD,Rachid Baz, MD,Brandon Blue, MD,Ken Shain, MD, PhD

February 8th 2023

Expert perspectives on a patient profile of transplant-ineligible multiple myeloma, with considerations for treatment selection and defining transplant ineligibility.

The Role of Teclistamab in Multiple Myeloma

ByAjai Chari, MD,Annel Urena,Kiah Purcell

February 8th 2023

Dr Ajai Chari explains the mechanism of action of BCMA-targeting bispecifics and the role of teclistamab in multiple myeloma treatment.

Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation

ByAjai Chari, MD,Annel Urena,Kiah Purcell

February 8th 2023

Anne-Marie Jacob describes her early treatment regimen for multiple myeloma and her experience with clinical trial enrollment.

Induction Therapy in Transplant-Ineligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 6th 2023

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Role of Transplant and Induction Therapies in NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 6th 2023

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

Selecting Treatment Regimens for Multiple Myeloma at First Relapse

BySagar Lonial, MD, FACP,Sandy Wong, MD,Caitlin Costello, MD,Timothy Schmidt, MD,Samuel M. Rubinstein, MD

February 6th 2023

Turning to the last module, expert panelists discuss the treatment armamentarium for patients experiencing early relapse in multiple myeloma.

Choosing the Right Treatment for Patients With Transplant Ineligible MM

BySagar Lonial, MD, FACP,Sandy Wong, MD,Caitlin Costello, MD,Timothy Schmidt, MD,Samuel M. Rubinstein, MD

February 6th 2023

Patient and disease factors that help to select best first-line therapy in the setting of transplant-ineligible multiple myeloma.

Optimal Selection of Therapy for Patients With Transplant-Eligible NDMM

ByBeth Faiman, PhD, MSN, APN-BC,Sandra Mazzoni, MD,Jack Khouri, MD,Louis Williams, MD

February 3rd 2023

A focused discussion on navigating the treatment armamentarium for patients with transplant-eligible newly diagnosed multiple myeloma.

Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma

ByBeth Faiman, PhD, MSN, APN-BC,Sandra Mazzoni, MD,Jack Khouri, MD,Louis Williams, MD

February 3rd 2023

Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider optimal workup and management strategies.

Joshua Richter, MD, an expert on multiple myeloma

Clinical Pearls and Unmet Needs in R/R Multiple Myeloma

ByJoshua Richter, MD

February 3rd 2023

Joshua Richter, MD, offers advice to community oncologists and discusses unmet needs in the treatment of patients with relapsed/refractory MM.

The Genetics of Multiple Myeloma: Expert Perspectives

ByONCOLOGY Staff

February 2nd 2023

Experts discuss the genetics of multiple myeloma, the prevalent testing paradigms in this space, and possibilities for the future.

Treatment Duration in Patients With Transplant-Ineligible NDMM

ByMelissa Alsina, MD,Rachid Baz, MD,Brandon Blue, MD,Ken Shain, MD, PhD

February 1st 2023

Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.

Transplant-Ineligible NDMM: Optimizing Therapy for Frailer Patients

ByMelissa Alsina, MD,Rachid Baz, MD,Brandon Blue, MD,Ken Shain, MD, PhD

February 1st 2023

Experts from the Moffit Cancer Center work to identify frail patients with transplant-ineligible NDMM and consider how best to select first-line therapy for this population.

Resources for Patient Education

ByAjai Chari, MD,Annel Urena,Kiah Purcell

February 1st 2023

Nurse Practitioner Kiah Purcell and Registered Nurse Annel Urena explain their role in the diagnosis and education of a patient with multiple myeloma.

A Patient’s Experience With a Multiple Myeloma Diagnosis

ByAjai Chari, MD,Annel Urena,Kiah Purcell

February 1st 2023

Ajai Chari, MD, provides a quick overview of multiple myeloma and patient Anne-Marie Jacob shares the story of her diagnosis.

DETERMINATION, GRIFFIN, and MASTER Studies

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

January 30th 2023

Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.

Induction Regimen Options in Transplant-Eligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

January 30th 2023

Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.

Approaching Induction Therapy for Patients With Transplant-Ineligible MM

BySagar Lonial, MD, FACP,Sandy Wong, MD,Caitlin Costello, MD,Timothy Schmidt, MD,Samuel M. Rubinstein, MD

January 30th 2023

Switching their focus to transplant-ineligible multiple myeloma, panelists review available triplet therapy regimens for induction therapy.

Selecting The Appropriate Treatment in Transplant-Eligible Newly Diagnosed MM

BySagar Lonial, MD, FACP,Sandy Wong, MD,Caitlin Costello, MD,Timothy Schmidt, MD,Samuel M. Rubinstein, MD

January 30th 2023

A brief discussion how to select the appropriate treatment strategy in transplant-eligible newly diagnosed myeloma and whether there is a role for minimal residual disease in assessing response and treatment duration.

Bispecific Antibodies in the Treatment of Multiple Myeloma

ByJoshua Richter, MD

January 27th 2023

An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.

Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple-Class Refractory MM

ByJoshua Richter, MD

January 27th 2023

An overview of recent data on selinexor, carfilzomib, and dexamethasone in triple-class refractory multiple myeloma, and treatment options to replace belantamab.

Bispecific Antibodies in Relapsed/Refractory MM: Future Perspectives

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 26th 2023

Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.

Appropriate Patient Selection for Cevostamab in Relapsed/Refractory MM

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 26th 2023

Shared insight on possible real-world applications for FcRH5-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

Selecting First-Line Therapy for Patients With Transplant-Ineligible NDMM

ByMelissa Alsina, MD,Rachid Baz, MD,Brandon Blue, MD,Ken Shain, MD, PhD

January 25th 2023

Moving on to review the management of transplant-ineligible NDMM, expert panelists highlight first-line treatment options with data from the SWOG0777 and MAIA studies.

Patient Profile 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma

ByMelissa Alsina, MD,Rachid Baz, MD,Brandon Blue, MD,Ken Shain, MD, PhD

January 25th 2023

Centering focus on a patient scenario of transplant-eligible newly diagnosed multiple myeloma, panelists consider the role of induction therapy and transplant in this setting.